drugset / Trial / NCT00684827

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

NCT00684827

Phase 2 Completed 32 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.

Timeline

Start
2002-10
Primary completion
2003-02
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levalbuterol Other / unclassified 45 ug Inhaled
Comparator racemic albuterol Unknown 90 ug Inhaled

Indications